Shockwave lithotripsy (SWL) is the gold standard treatment of patients with most renal and proximal ureteral calculi. Severe bleeding complications in SWL are extremely rare. Uncorrected bleeding diathesis might increase the risk and is considered to be an absolute contraindication for SWL. Perioperative management of anticoagulative and antiplatelet therapy has changed in the recent past. In particular, low-dose acetylsalicylic acid (ASA) is no longer a contraindication for many surgical procedures.
Methods:
A systematic Medline/PubMed literature search of peer-reviewed scientific articles in urology and cardiovascular medicine was performed concerning the management of anticoagulative and antiplatelet medication during SWL.
Results:
The literature on medically acquired and pathological bleeding diathesis and SWL in general is rare, retrospective, nonstandardized, and of low quality. Routine cessation of obligatory indicated anticoagulative or antiplatelet medication implies a significant risk for cardiovascular adverse events (CAE). Ureterorenoscopy is recommended in patients with uncorrected bleeding diathesis, although this is not based on high-level evidence.
Conclusion:
In patients with obligatory intake of anticoagulative or antiplatelet medication, the risk for CAE must be balanced against the SWL-induced bleeding risk. In patients with low-dose ASA-intake, SWL should be considered as an option instead of being disregarded as an absolute contraindication. Prospective randomized trials designed to define the optimal management of anticoagulants and antiplatelets during SWL are warranted.
Get full access to this article
View all access options for this article.
References
1.
TürkC, KnollT, PetrikA, et al.2013. The EAU Guidelines on Urolithiasis. Available at: http://www.uroweb.org/guidelines/online-guidelines/. Accessed: June23, 2014.
2.
SkolarikosA, AlivizatosG, de la RosetteJ. 2006. Extracorporeal shock wave lithotripsy 25 years later: Complications and their prevention. Eur Urol, 2006; 50:981–990.
3.
BaronTH, KamathPS, McBaneRD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med, 2013; 368:2113–2124.
4.
DouketisJD, SpyropoulosAC, SpencerFA, et al; American College of Chest Physicians. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012; 141(suppl 2):e326S–e350S.
5.
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996; 348 (9038):1329–1339.
6.
YusufS, ZhaoF, MehtaSR, et al; Clopidogrel in Unstable Angin to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001; 345:494–502.
7.
BrilakisES, PatelVG, BanerjeeS. Medical management after coronary stent implantation: A review. JAMA, 2013; 310:189–198.
8.
DunningJ, VersteeghM, FabbriA, et al; EACTS Audit and Guidelines Committee. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg, 2008; 34:73–92.
9.
HolbrookA, SchulmanS, WittDM, et al; American College of Chest Physicians. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012; 141(suppl 2):e152S–e184S.
10.
OddenMC, CoxsonPG, MoranA, et al.The impact of the aging population on coronary heart disease in the United States. Am J Med, 2011; 124:827–833.e5.
11.
PoldermansD, BaxJJ, BoersmaE, et al; Assessment TFfPCR, Cardiology PCMiN-cSoESo, Anaesthesiology ESo. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol, 2010; 27:92–137.
12.
IakovouI, SchmidtT, BonizzoniE, et al.Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA, 2005; 293:2126–2130.
13.
BurgerW, ChemnitiusJM, KneisslGD, RückerG. Low-dose aspirin for secondary cardiovascular prevention—cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation—review and meta-analysis. J Intern Med, 2005; 257:399–414.
14.
OscarssonA, GuptaA, FredriksonM, et al.To continue or discontinue aspirin in the perioperative period: A randomized, controlled clinical trial. Br J Anaesth, 2010; 104:305–312.
15.
KeferJC, DesaiMM, FerganyA, et al.Outcomes of partial nephrectomy in patients on chronic oral anticoagulant therapy. J Urol, 2008; 180:2370–2374, 2734.
16.
McAteerJA, EvanAP. The acute and long-term adverse effects of shock wave lithotripsy. Semin Nephrol, 2008; 28:200–213.
17.
LeeHY, YangYH, ShenJT, et al.Risk factors survey for extracorporeal shockwave lithotripsy-induced renal hematoma. J Endourol, 2013; 27:763–767.
18.
Collado SerraA, Huguet PérezJ, Monreal García de VicuñaF, et al.Renal hematoma as a complication of extracorporeal shock wave lithotripsy. Scand J Urol Nephrol, 1999; 33:171–175.
19.
RazviH, FullerA, NottL, et al.Risk factors for perinephric hematoma formation after shockwave lithotripsy: A matched case-control analysis. J Endourol, 2012; 26:1478–1482.
20.
Torrecilla OrtizC, Matías LópezJJ, Contreras GarcíaJ, et al.[Renal hematoma after shockwave extracorporeal lithotripsy.]. (Spa) Actas Urol Esp, 1997; 21:752–757.
21.
SchnabelMJ, GierthM, ChaussyCG, et al.Incidence and risk factors of renal hematoma: A prospective study of 1,300 SWL treatments. Urolithiasis, 2014; 42:247–253.
22.
RubinJI, ArgerPH, PollackHM, et al.Kidney changes after extracorporeal shock wave lithotripsy: CT evaluation. Radiology, 1987; 162:21–24.
23.
BaumgartnerBR, DickeyKW, AmbroseSS, et al.Kidney changes after extracorporeal shock wave lithotripsy: Appearance on MR imaging. Radiology, 1987; 163:531–534.
24.
KaudeJV, WilliamsCM, MillnerMR, et al.Renal morphology and function immediately after extracorporeal shock-wave lithotripsy. AJR Am J Roentgenol, 1985; 145:305–313.
25.
FischerC, WöhrleJ, PastorJ, et al.[Extracorporeal shock-wave lithotripsy induced ultrastructural changes to the renal parenchyma under aspirin use. Electron microscopic findings in the rat kidney.] (Ger) Urologe A, 2007; 46:150–155.
26.
KlinglerHC, KramerG, LoddeM, et al.Stone treatment and coagulopathy. Eur Urol, 2003; 43:75–79.
27.
LiC, HirshJ, XieC, JohnstonMA, EikelboomJW. Reversal of the anti-platelet effects of aspirin and clopidogrel. J Thromb Haemost, 2012; 10:521–528.
28.
ZismanE, ErportA, KohanovskyE, et al.Platelet function recovery after cessation of aspirin: Preliminary study of volunteers and surgical patients. Eur J Anaesthesiol, 2010; 27:617–623.
29.
KnorrPA, WoodsideJR. 1990. Large perirenal hematoma after extracorporeal shock-wave lithotripsy. Urology, 1990; 35:151–153.
30.
RuizH, SaltzmanB. Aspirin-induced bilateral renal hemorrhage after extracorporeal shock wave lithotripsy therapy: Implications and conclusions. J Urol, 1990; 143:791–792.
31.
SareGM, LloydFR, StowerMJ. Life-threatening haemorrhage after extracorporeal shockwave lithotripsy in a patient taking clopidogrel. BJU Int, 2002; 90:469.
32.
BahceciM, TuzcuA, AkayF, et al.Serious clopidogrel associated renal hematoma in a type 2 diabetic patient with primary hyperparathyroidism after extracorporeal shock wave lithotripsy. Saudi Med J, 2005; 26:1007–1009.
UedaS, MatsuokaK, YamashitaT, et al.Perirenal hematomas caused by SWL with EDAP LT-01 lithotripter. J Endourol, 1993; 7:11–15.
36.
MukerjiG, MunasingheI, RazaA. A survey of the peri-operative management of urological patients on clopidogrel. Ann R Coll Surg Engl, 2009; 91:313–320.
37.
ZanettiG, Kartalas-GoumasI, MontanariE, et al.Extracorporeal shockwave lithotripsy in patients treated with antithrombotic agents. J Endourol, 2001; 15:237–241.
38.
RomeoG, SalanitriG, CataniaG. Time-course of anti-Xa effects of calcium heparin and low-molecular-weight heparin given s.c.: Insights for thrombosis prevention. Drugs Exp Clin Res, 1988; 14:423–427.
39.
GrinesCL, BonowRO, CaseyDEJr, et al.2007. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol, 2007; 49:734–739.
SavonittoS, D'UrbanoM, CaraccioloM, et al.Urgent surgery in patients with a recently implanted coronary drug-eluting stent: A phase II study of ‘bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth, 2010; 104:285–291.
42.
Ben MorrisonT, HorstBM, BrownMJ, et al.Bridging with glycoprotein IIb/IIIa inhibitors for periprocedural management of antiplatelet therapy in patients with drug eluting stents. Catheter Cardiovasc Interv, 2012; 79:575–582.
43.
RassiAN, BlackstoneE, MilitelloMA, et al.2012. Safety of “bridging” with eptifibatide for patients with coronary stents before cardiac and non-cardiac surgery. Am J Cardiol, 2012; 110:485–490.
44.
HuangPH, CroceKJ, BhattDL, ResnicFS. Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation. Crit Pathw Cardiol, 2012; 11:177–185.
45.
SighinolfiMC, MicaliS, GrandeM, et al.Extracorporeal shock wave lithotripsy in an elderly population: How to prevent complications and make the treatment safe and effective. J Endourol, 2008; 22:2223–2226.
46.
SiegalD, YudinJ, KaatzS, et al.Periprocedural heparin bridging in patients receiving vitamin K antagonists: Systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation, 2012; 126:1630–1639.
47.
AboumarzoukOM, SomaniBK, MongaM. Flexible ureteroscopy and holmium:YAG laser lithotripsy for stone disease in patients with bleeding diathesis: A systematic review of the literature. Int Braz J Urol, 2012; 38:298–306.
48.
ToepferNJ, BaylorK, HenryY, et al.The effect of antiplatelet and anticoagulant therapy on the clinical outcome of patients undergoing ureteroscopy. Urology, 2013; 82:773–779.
49.
AboumarzoukOM, KataSG, KeeleyFX, NabiG. Extracorporeal shock wave lithotripsy (ESWL) versus ureteroscopic management for ureteric calculi. Cochrane Database Syst Rev, 2011:CD006029.
50.
BaiJ, LiC, WangS, et al.Subcapsular renal haematoma after holmium:yttrium-aluminum-garnet laser ureterolithotripsy. BJU Int, 2012; 109:1230–1234.
51.
ChiuPK, ChanCK, MaWK, et al.Subcapsular hematoma after ureteroscopy and laser lithotripsy. J Endourol, 2013; 27:1115–1119.
52.
PriceMJ, WalderJS, BakerBA, et al.Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: The recovery trial. J Am Coll Cardiol, 2012; 59:2338–2343.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
